Stoke Therapeutics, Inc. (STOK) |
|
7.65 -0.22 (-2.8%)
|
03-24 16:00 |
|
Open: |
7.82 |
Pre. Close: |
7.87 |
|
High:
|
7.82 |
Low:
|
7.215 |
|
Volume:
|
272,999 |
Market Cap:
|
338(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:30:13 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 10.43  One year: 11.66 |
| Support: |
Support1: 7.21 Support2: 6 |
| Resistance: |
Resistance1: 8.92 Resistance2: 9.98 |
| Pivot: |
8.77 |
| Moving Average: |
MA(5): 7.99 MA(20): 8.77
MA(100): 9.07 MA(250): 12.77 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 8.3  %D(3): 6.8 |
| RSI: |
RSI(14): 34.1 |
| 52-week: |
High: 24.96 Low: 6.88 |
| Average Vol(K): |
3-Month: 334 (K) 10-Days: 286 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ STOK ] has closed above bottom band by 4.6%. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.83 - 7.89 |
7.89 - 7.94 |
|
Low:
|
7.09 - 7.16 |
7.16 - 7.2 |
|
Close:
|
7.56 - 7.67 |
7.67 - 7.74 |
|
Company Description |
|
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. |
Headline News |
Thu, 23 Mar 2023
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus ... - MarketBeat
Wed, 15 Mar 2023
Stoke Therapeutics Says US FDA to Approve Higher Single Dose of Proposed Dravet Syndrome Treatment - Marketscreener.com
Wed, 15 Mar 2023
Stoke Therapeutics Announces That FDA Will Allow the ... - Business Wire
Wed, 08 Mar 2023
Even after rising 5.6% this past week, Stoke Therapeutics (NASDAQ:STOK) shareholders are still down 56% over the past year - Simply Wall St
Mon, 06 Mar 2023
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 ... - Business Wire
Mon, 06 Mar 2023
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
1.472e+007 (%) |
|
% Held by Institutions
|
6.2 (%) |
|
Shares Short
|
3,840 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.0053e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
113.1 |
|
Return on Equity (ttm)
|
-24 |
|
Qtrly Rev. Growth
|
9.14e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-113.05 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-2.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-26 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.07 |
|
Price to Cash Flow
|
0.47 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.82e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
